Orchestra BioMed (NASDAQ:OBIO) & BATM Advanced Communications (OTCMKTS:BTAVF) Financial Contrast

BATM Advanced Communications (OTCMKTS:BTAVF – Get Free Report) and Orchestra BioMed (NASDAQ:OBIO – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares BATM Advanced Communications and Orchestra BioMed’s net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BATM Advanced Communications and Orchestra BioMed, as provided by MarketBeat.com.

Orchestra BioMed has a consensus price target of $13.60, indicating a potential upside of 220.75%. Given Orchestra BioMed’s stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than BATM Advanced Communications.

Institutional & Insider Ownership

53.2% of Orchestra BioMed shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares BATM Advanced Communications and Orchestra BioMed”s gross revenue, earnings per share (EPS) and valuation.

BATM Advanced Communications has higher earnings, but lower revenue than Orchestra BioMed.

Summary

Orchestra BioMed beats BATM Advanced Communications on 6 of the 9 factors compared between the two stocks.

About BATM Advanced Communications

(Get Free Report)

BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in Networking and Cyber, and Bio-Medical divisions. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization, carrier ethernet and MPLS access solutions, and cyber network monitoring. It also offers software services, such as training and technical support, laboratory service and maintenance; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.

About Orchestra BioMed

(Get Free Report)

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.